Alligator receives the SwedenBIO Award!

Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another confirmation of Alligator´s success in the field.  Alligator is a privately held Swedish biotech company with a pipeline of immune-activating antibodies for tumor-directed immunotherapy of cancer. Notably, in 2015 Alligator granted Janssen Biotech Inc, one of the Janssen Pharmaceutical companies of Johnson & Johnson, an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013. Under the agreement Alligator receives an initial up-front payment and aggregated future milestones up to a potential total of 700 MUSD.

Alligator Bioscience is a privately held biotech company located in Lund, Sweden. The company was founded in 2001 and has 35 employees.

About Us

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees.


Documents & Links